Story perspectives

eGenesis' Gene-Edited Pig Kidneys Show Promise in Trials

9/12/2025

26 6

Summary

Story summary

eGenesis, a Massachusetts company, gained FDA clearance for a clinical trial of gene-edited pig kidneys for end-stage kidney disease (ESKD) patients.
The Phase 1/2/3 trial will evaluate the safety and efficacy of EGEN-2784 over 24 weeks in patients aged 50 and older.
EGEN-2784 includes three gene edits to improve compatibility and reduce rejection risk.
Early results show promise, with Tim Andrews, 67, living without dialysis for over seven months post-transplant, and Bill Stewart, 54, discharged a week after receiving a kidney.
eGenesis aims to tackle the global organ shortage with this innovative solution.

1 of 1

Story summary

eGenesis, a Massachusetts company, gained FDA clearance for a clinical trial of gene-edited pig kidneys for end-stage kidney disease (ESKD) patients.
The Phase 1/2/3 trial will evaluate the safety and efficacy of EGEN-2784 over 24 weeks in patients aged 50 and older.
EGEN-2784 includes three gene edits to improve compatibility and reduce rejection risk.
Early results show promise, with Tim Andrews, 67, living without dialysis for over seven months post-transplant, and Bill Stewart, 54, discharged a week after receiving a kidney.
eGenesis aims to tackle the global organ shortage with this innovative solution.